Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

CMS proposes the 2026 Physician Fee Schedule, addressing payment disparities in oncology, but warns of financial threats from ...

Essa Pharma, which had been resisting pressure from activist investors to wind down operations, has now agreed a deal to ...

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.